ABSTRACT A prospective randomized study comparing coronary bypass surgery (group 1, 51 patients) to drug therapy (group 2, 49 patients) was initiated in 1981. Supine graded exercise testing (SGXT) was performed initially, at 6 months, and annually with a bicycle ergometer. The presence or absence of ischemic ST segment changes (positive or negative SGXT) and chest pain were recorded. Initially, 63% of all patients had positive SGXT. For group 2, the frequency of positive SGXT results did not change significantly at 6 months (58%) or at 5 years (52%). At 6 months the number of patients without chest pain increased in group 1 compared with group 2 (28/41 vs 13/41, respectively; p < .002), but there was no difference in the frequency of positive SGXT results (20/41 vs 24/41, respectively; p = NS). This occurred because a majority of the group 1 patients with positive SGXT no longer had associated chest pain (group 1, 11/20, group 2, 3/24; p < .007). This response was associated with incomplete revascularization in eight of these 11 group 1 patients and may result from "silent ischemia." At 5 years, no significant difference existed in the incidence of positive SGXT (group 1, 10/32 vs group 2, 12/23; p = NS), but group 1 patients continued to have a reduction (although not statistically significant) in the number of patients without chest pain (group 1, 19/32 vs group 2, 7/23). The incidences of death and myocardial infarction were not significantly different between groups. Fewer episodes of unstable angia occurred in group 1 (10/51 vs 19/49; p < .05). The prognosis of group 1 patients with positive SGXT and no chest pain and incomplete revascularization was not different from that of the entire group.
Methods
Details of the trial have been described previously.1' 2 Candidates for the trial had disabling angina pectoris (functional class III or IV despite therapy) for at least 1 year, were 62 years of age or younger, had no episodes of unstable angina or myocardial infarction within 6 months, had no clinical evidence of heart failure or cardiomegaly, and had no other major disabling illnesses. After 5 years, 100 patients were enrolled, 51 in the surgical treatment group (group 1) and 49 in the drug treatment group (group 2). All patients underwent coronary and left ventricular angiography and SGXT. Coronary angiography was performed by the Judkins technique.3 The results were evaluated independently by two observers, and any differences were reconciled by concordance. If one or more major coronary arteries had more than 50% reduction in luminal diameter and the distal vessel was suitable for grafting, the patient was randomly assigned to drug or surgical therapy. Patients with left main coronary artery disease were excluded.
SGXT was performed with a bicycle ergometer. Exercise was initiated at a low workload, usually 200 kilopond-meters, and increased in 200 kpm increments at 3 min intervals, with a brief rest between exercise periods, until the patient was unable to continue because of dyspnea, fatigue, or chest pain. Interrupted exercise was used because it provides a more precise determination of heart rate and systolic blood pressure product at the threshold of angina.4' 5 Exercise was stopped by the physician if serious cardiac arrhythmias developed. Almost all patients had stopped taking propranolol and nitroglycerin 24 hr before their initial and 6 month tests; however, only about half of the patients had stopped taking these medications before the 5 year test. The electrocardiogram (ECG) (lead CM5) was monitored continuously and was recorded at the end of each level of exercise and at intervals during the recovery period. Horizontal At 5 years the proportion of patients with a positive SGXT in group 2 had decreased slightly to 52%, but this did not differ significantly from their initial results. The association between a positive SGXT and chest pain was still present at 5 years, with 10 of 12 (83%) group 2 patients with a positive SGXT having associated chest pain. Group 2 had a 32% prevalence of positive SGXT at 5 years, a significant reduction compared with the initial studies (p < .025).
There was no significant difference in the prevalence of positive SGXT between the two groups at 5 years. Group achieve a maximum workload and heart rate that were significantly higher than initial values and similar to the results at 6 months. Because of the small increase (p = NS) in maximum workload of group 2 patients and the small decrease (p = NS) in maximum heart rate of group 1 patients, there was no significant difference in these variables between the two groups at 5 years.
As mentioned above, a positive exercise test was usually associated with chest pain in the initial studies this was the case in 88% of positive tests in group 2 and 96% in group 2 (figure 1). This was still true in 88% of group 2 patients at 6 months and 83% at 5 Table 4 shows the relationship between the results of the exercise test at 6 months and the success of revascularization in all patients who had a positive exercise test initially. Revascularization was considered successful if all significantly obstructed major arteries were bypassed and all grafts were patent at the 6 month study. If all major distal vessels could not be bypassed, or one or more grafts were occluded or had a greater than 90% diameter stenosis, revascularization was considered incomplete. When revascularization was incomplete, 89% of the patients with an initially positive SGXT had a positive SGXT after surgery. This was true for eight of nine patients in the subgroup with a positive SGXT without associated chest pain at 6 months after surgery (two did not have a positive SGXT initially). If revascularization was successful, only 18% of the patients with a positive SGXT initially had a positive SGXT after surgery. Thus a significant association exists between the success of revascularization and the results of the SGXT (p < .001).
Major clinical events. Table 5 shows the major clinical events for groups 1 and 2 and for the subgroup with a positive SGXT without chest pain at 6 months. The incidence of death and myocardial infarction were not significantly different between groups I and 2, and fewer episodes of unstable angina occurred in the sur- AGroup 1 patients, n = 24; group 2 patients who underwent subsequent bypass graft surgery, n = 6.
BSuccessful revascularization was associated with a negative SGXT after surgery, while incomplete revascularization was associated with persistence of positive SGXT (p < .001). gically treated groups (p < .05). In the subgroup with a positive SGXT without chest pain at 6 months, the incidence of major clinical events and the reduction in episodes of unstable angina were similar to those of group 1 as a whole.
CIRCULATION
Discussion SGXT results: groups 1 and 2. A positive SGXT and associated chest pain were present initially in most (63%) patients with histories of exertional chest pain and documented coronary artery disease. Group 2 had no change in positive SGXT results, associated chest pain, maximum workload, and maximum heart rate 6 months and 5 years after entry into the study. In contrast, in group 1 there was a significant reduction in the incidence of positive SGXT results and associated chest pain, and a substantial improvement in maximum workload and maximum heart rate at 6 present at 5 years in the frequency of abnormal SGXT or the maximum heart rate and workload achieved. This was due to slight, but not statistically significant, changes in each group. The number of patients who died or had a myocardial infarction was similar in both groups. Thus the extended benefits in group 1 patients were a lower incidence of chest pain during SGXT and fewer episodes of unstable angina..
Propranolol and SGXT results. Some patients performed their exercise tests while taking propranolol, despite our plans to avoid this, especially at the 5 year study. Some patients forgot to stop taking the propranolol 24 hr before study or refused to stop because their angina became worse. Two groups have shown that ,Bblockers had no effect on ST-T depression during exercise testing in patients with coronary artery disease."', 12 Our data show that the results of exercise testing (ST segment depression or the number of patients who experienced pain) were not affected by the use of propranolol in some patients.
Discrepancy between objective and subjective signs of ischemia after surgery. A positive SGXT was almost always associated with chest pain in the initial studies. This was still the pattern in group 2 patients at 6 months. However, after surgery, 60% of group 1 patients with a positive SGXT no longer had associated chest pain, a significant change compared with group 2. Almost all of these patients had a positive SGXT with chest pain initially.
Others have described a similar group of patients after bypass graft surgery. Mnayer et al.6 reported that 13 surgical patients (59% of the group) had ST depression without angina; this response occurred in only 9% (3/35) of drug-treated patients. Bartel et al.7 reported that 56% (19/34 patients) continued to have a positive exercise test after surgery but no longer had chest pain. Berndt et al."3 found that 33% of patients that had exercise testing after surgery for unstable angina no longer had chest pain but had a positive exercise test. None of these patients had preoperative exercise tests because of the unstable angina.
The mechanism underlying the absence of angina despite ischemic ST segment depression on an exercise test is unclear. This response is seen most commonly after bypass graft surgery, but the role the surgery plays in "causing" this response is not understood.
Suggested mechanisms include (1) perioperative infarction of ischemic tissue, 1l6 (2) placebo effect of surgery,' 18 and (3) denervation of ischemic areas." '16 Analysis of our patients with a positive SGXT and no chest pain after surgery indicated that none of the variables shown in 23 found that symptomatic episodes of ischemia were longer than asymptomatic episodes and were associated with more severe left ventricular dysfunction. These reports suggest that during ischemia not accompanied by chest pain, the severity of ischemia may be less marked, the area or mass of myocardium involved may be less extensive, or both, than in myocardial ischemia associated with pain. It may be that in the patients with a positive SGXT without chest pain the surgery, although it was not completely successful, reduced the area or severity of ischemia, or both, so that chest pain did not occur with the amount of work done during the SGXT but would probably occur with more severe exertion. Radionuclide studies might indicate whether ischemia was present during exertion, but these techniques were not available at the beginning of our trial. Since this response (positive SGXT without chest pain) is associated with byass graft surgery, it is possible that placebo effect, denervation of ischemic areas, or perioperative infarction play some role in the relief of pain. 418 The significance or risk of myocardial ischemia without chest pain is not clear. Patients who do not experience angina during myocardial ischemia may lack an important warning to stop an activity before there is potentially fatal damage to the myocardium or induction of arrhythmias.724 Conversely, the prognosis of "silent" ischemia may not be worse than that of symptomatic ischemia. 25 We have a small group of patients and firm conclusions are difficult to make, but their incidence of death (including sudden death) and myocardial infarction were not significantly different than those of group 2 and other group 1 patients. It is possible that important differences could not be detected between our groups because of a type II or beta error. With the sample sizes of 49 and 51 patients, a significance level of .05 and actuarial curve analysis, we have calculated that a difference of 7% per year between the two groups over a 5 year period for each major clinical event would be detected with a power of 0.90, that is, there is a 10% chance that such a difference could be missed. For differences of 6% and 5% per year, the discriminatory powers are 0.80 and 0.70, respectively. When smaller subgroups are considered, such as those patients with continued positive SGXT but loss of chest pain, the discriminating power becomes weaker and the probability of a type II error greater. For this reason, one must be cautious in interpreting the "nonsignificant" results in this study, particularly in subgroups of patients.
In summary, SGXT results showed that our surgically treated group had a significant decrease in the number of patients with a positive SGXT and in the number with chest pain, and a significant increase in work capacity up to 5 years after surgery, compared with preoperative results. When the results from the surgically treated group were compared with those of the drug-treated group at 5 years of follow-up, the surgically treated group had fewer episodes of unstable angina. There was no difference in the frequency of abnormal SGXT results, the frequency of chest pain during SGXT, the maximum heart rate and workload achieved, or in the incidence of death or myocardial infarction between the groups.
About half of patients that still had a positive SGXT after surgery no longer had associated chest pain. This response was associated with incomplete revascularization in 80% of these patients. The persistence of the positive SGXT is probably caused by myocardial ischemia; the absence of pain may indicate less severe myocardial ischemia than that associated with pain. Survival in these patients may not be different than that of drug-or other surgically treated patients.
